Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Mallinckrodt
Baxter
UBS
McKesson
Federal Trade Commission
Moodys
Boehringer Ingelheim

Generated: June 19, 2018

DrugPatentWatch Database Preview

ERGOLOID MESYLATES - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for ergoloid mesylates and what is the scope of ergoloid mesylates freedom to operate?

Ergoloid mesylates
is the generic ingredient in eight branded drugs marketed by Novartis, Mutual Pharm, Sun Pharm Industries, Watson Labs, Sandoz, 3M, Bristol Myers Squibb, Kv Pharm, Lederle, Superpharm, Vangard, and Ivax Pharms, and is included in thirty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for ergoloid mesylates. Two suppliers are listed for this compound.
Medical Subject Heading (MeSH) Categories for ERGOLOID MESYLATES

US Patents and Regulatory Information for ERGOLOID MESYLATES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kv Pharm ERGOLOID MESYLATES ergoloid mesylates TABLET;SUBLINGUAL 085899-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ivax Pharms HYDROGENATED ERGOT ALKALOIDS ergoloid mesylates TABLET;SUBLINGUAL 087185-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs ERGOLOID MESYLATES ergoloid mesylates TABLET;SUBLINGUAL 084930-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Kv Pharm ERGOLOID MESYLATES ergoloid mesylates TABLET;SUBLINGUAL 086265-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for ERGOLOID MESYLATES

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis HYDERGINE LC ergoloid mesylates CAPSULE;ORAL 018706-001 Jan 18, 1983 ➤ Sign Up ➤ Sign Up
Novartis HYDERGINE ergoloid mesylates SOLUTION;ORAL 018418-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Medtronic
UBS
Johnson and Johnson
QuintilesIMS
Cerilliant
Accenture
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.